Innovation & intellectual property · 16/10/2007Updated: 10/17/2026 · 1 min read
U.S. Patent Office Grants Interim Extension to MEDIASANTE Biopharma's MIFAMURTIDE Patent
Summary
The U.S. Patent and Trademark Office has issued a certificate under 35 U.S.C. 156(d)(5) for a one-year interim extension of the term of U.S. Patent No. 4,971,802, covering MEDIASANTE Biopharma's MIFAMURTIDE, a treatment for multiple myeloma.
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →